Impact of new criteria

Webinar: Endocrine disruptors and biocides – what you need to know
19 June 2018

Simon Gutierrez Alonso
Biocides Assessment
Contents

- Journey here
- Endocrine disruptor criteria
- Expected impact
- Recommendations
Journey to ED criteria under biocides

June 2016
European Commission
draft criteria

November 2017
Criteria published

7 June 2018
Criteria apply

Guidance published for the identification of endocrine disruptors in the context of biocides and plant protection products
Endocrine disruptor criteria
Criteria for humans and non-target organisms

• ED properties need to be assessed for both humans and non-target organisms – **but** not the organism (same taxonomic phylum) the biocide is targeted against

• ED properties with respect to **humans**
  • ED criteria (definition of what constitutes an endocrine disruptor)
  • How to determine whether the criteria are met

• ED properties with respect to **non-target organisms**
  • ED criteria (definition of what constitutes an endocrine disruptor)
  • How to determine whether the criteria are met
A substance is considered as having endocrine disrupting properties if it meets **all** of the following criteria:

a) it shows an adverse effect in an intact organism or its progeny (offspring)

b) it has an endocrine mode of action, that is, it alters the function(s) of the endocrine system

c) the adverse effect is a consequence of the endocrine mode of action
How to assess the ED properties

• Assessment is based on ‘all available relevant scientific data’

• **Weight of evidence approach** is applied in the assessment, considering factors such as:
  
  • **Relevance of the study** design for the assessment of adverse effects and endocrine activity
  
  • Positive and negative results (i.e. **consistency of the results**)
  
  • **Coherence** of the (pattern of) results within and between studies and across species
  
  • **Biological plausibility** of the link between the endocrine activity and the adverse effects, i.e. the endocrine mode of action
Expected impact
Active substance approval

- Applicant
  - Dossier submission
  - Applicant comments

- Evaluating Member State
  - Dossier evaluation
  - Competent authority report

- ECHA
  - Commenting by Member States
  - Working Groups
    - Opinion of Biocidal Products Committee

- Commission & Standing Committee
  - Decision on approval
Biocidal Products Committee gives its opinion

• BPC gives opinions on behalf of ECHA for active substance approval and renewal

• BPC working groups (on human health and environment) carry out scientific work in preparation for BPC opinions

• **From now on**, all BPC opinions need to contain an ED assessment according to the new criteria

• If an opinion has already been adopted but a decision is not yet taken by the European Commission and Member States ➔ ED assessment will need to take place before final decision
ED expert group gives advice

- Established in 2013 by agreement of competent authorities for REACH and biocides
- Provides **informal** and **non-binding scientific advice** on assessment of ED properties
  - Support screening to identify potential EDs
  - Give feedback on interpretation of available data and identification of further information requirements and strategy to fill data gaps
  - Contribute to developing testing and assessment approaches
  - Contribute to case discussions with the eCA
- **Does not** take formal decisions → these remain the responsibility of competent authorities for biocides and is within the remits of BPC and BPC-WGs
ED expert group set up

- 3 meetings a year hosted by ECHA
- 50 external members
- There are open and closed sessions, experts nominated by stakeholders may participate only the open sessions

<table>
<thead>
<tr>
<th>Authorities: Member States and EEA (17)</th>
<th>AT, BE, DE, DK, EL, FI, FR, IE, IT, LT, NL, PL, RO, SE, SK, UK, NO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Industry stakeholders</td>
<td>CEFIC, ECETOC</td>
</tr>
<tr>
<td>Public interest stakeholders</td>
<td>EEB, HEAL, CHEMtrust, HSI, ETUC</td>
</tr>
<tr>
<td>European Commission</td>
<td>DG GROW, DG ENV, DG JRC, DG SANTE</td>
</tr>
<tr>
<td>Others</td>
<td>CH, OECD, EFSA</td>
</tr>
</tbody>
</table>
Are ED properties clearly indicated?

Route to final decision

Company submits an application
Competent authority evaluates
Competent authority submits a report to ECHA
BPC working group
BPC opinion

ED expert group

European Commission
echa.europa.eu
Active substance – consequence of identifying it as an ED

ED for humans

• Fulfils exclusion criteria and shall **not** be approved (BPR art. 5)
• Can be approved if one of the derogation conditions is met:
  • **Risk** from exposure is **negligible**
  • **Essential** to prevent or control a serious danger to human or animal health or the environment
  • Non-approval would have a **disproportionate negative impact** on society when compared with the risk
Active substance – consequence of identifying it as an ED

ED for non-target organisms

• Meets the substitution criteria but can be approved (BPR art. 10)
• Products containing the active substance
  • will not be authorised for use by the general public
  • will only be authorised for professional use if there are no alternatives on the market
• The same consequences apply if the intended biocidal mode of action consists of controlling target organisms via their endocrine system(s)
Data requirements 1/2

• Assessment submitted **before** 1 September 2013
  • Opportunity for companies to submit additional information on ED properties

• Assessment submitted **after** 1 September 2013
  • National authority can require additional information

Submission ➔ Evaluating authority submits the report to ECHA
Data requirements 2/2

- Evaluating authority may need additional information to assess the active substance and to decide whether or not it has ED properties.

- The current data requirements (Annex II to BPR) were drafted when the ED criteria and the guidance did not yet exist.

- Discussions are ongoing on the need to revise the requirements.
Biocidal products
Product authorisation

- Applicants and eCAs need to determine in the product assessment report, whether the product is considered to have ED properties or not.
- Not be authorised for use by the general public.
Co-formulants (non-active substances)

- Evaluating authority has to decide whether there is a need to evaluate a specific non-active substance in detail and, if necessary, to ask more information from the applicant.
- This should only occur when there are indications that a non-active substance may have ED properties, based on existing knowledge and the available scientific information.
Product families—consequences of identifying them as an ED

• All individual products of a family always contain the same active substance → all products are affected if the active substance is considered to have ED properties

• Individual products of a family contain non-active substances with ED properties → decision not to authorise use for general public is limited to these products only. You must group the affected products in the same ‘summary of product characteristics’ targeted for professional users only
Products already authorised

• If the conditions for product authorisation are no longer met, authorisation will be **amended or cancelled**

• Could be triggered by new information on ED properties of
  • the active substance in the product
  • of co-formulants

• As product authorisation holder, you have to **notify** the evaluating authority, ECHA or Commission if you become aware of such information

• If action is launched to amend or cancel an authorisation:
  • You will be informed
  • You will be able to submit comments and additional information
Products to be renewed

- Evaluating authority will assess whether the conditions for the product’s authorisation are still met

- If the conditions for authorisation are no longer met, the authorisation will not be renewed
Take home

• Start working now: challenge the data available and proactively engage in discussions with your evaluating authority
• Read through the guidance and start working based on the advice
• Plan resources and expertise to prepare and defend your applications. Ask for support if needed
To conclude

• New ED criteria is now applicable
• New guidance is available—start preparing now
• This is a learning process for all actors